Healing of resistant corneal neurotrophic ulcers using a matrix regenerating agent
作者： B. Cochener , C. Zagnoli , C. Hugny-Larroque , S. Derrien
DOI: 10.1016/J.JFO.2018.05.009
关键词: In patient 、 Surgical treatment 、 Surgery 、 Keratitis 、 Adjunctive treatment 、 Medical treatment 、 Neurotrophic corneal ulcer 、 Medicine
摘要: Summary Purpose To assess the success rate of a matrix regenerating agent (RGTA) in treatment chronic corneal ulcers resistant to conventional treatments. Methods Uncontrolled prospective observational study patients with neurotrophic ulcer (Stage 2 or 3 Mackie classification), unresponsive standard medical surgical treatments and managed RGTA as an adjunctive treatment. Corneal were evaluated using slit-lamp examination optical coherence tomography after weeks, 1 month, months months. Success was defined complete healing. Results administered 20 (20 eyes) various causes, including keratoplasty (7 eyes, 35.0%), herpetic keratitis (5 25.0%) intracorneal ring (3 15.0%). Total healing observed 13/20 (65.0%) within discontinued due partial healing/ulcer stagnation 6 (30.0%), aggravation patient (5.0%). Relapses reported 4 (20.0%) several cessation No adverse reactions noted. Conclusions In event failure treatments, may be alternative for ulcers, avoiding need resort
em-consulte.com参考文章(19)
Antonio Mateo, Beatriz Abadía, Pilar Calvo, Enrique Minguez, Luis Pablo, José Manuel Benitez del Castillo, Treatment of Acanthamoeba neurotrophic corneal ulcer with topical matrix therapy Journal of Ophthalmic Inflammation and Infection. ,vol. 5, pp. 18- 18 ,(2015) , 10.1186/S12348-015-0048-X
F. T. Fraunfelder, F. H. Roy, Current Ocular Therapy ,(1980)
Gabriel Sosne, Patricia L. Christopherson, Ronald P. Barrett, Rafael Fridman, Thymosin-β4 Modulates Corneal Matrix Metalloproteinase Levels and Polymorphonuclear Cell Infiltration after Alkali Injury Investigative Ophthalmology & Visual Science. ,vol. 46, pp. 2388- 2395 ,(2005) , 10.1167/IOVS.04-1368
Abdelouahab Aifa, Julie Gueudry, Alexandre Portmann, Agnès Delcampe, Marc Muraine, Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers. Investigative Ophthalmology & Visual Science. ,vol. 53, pp. 8181- 8185 ,(2012) , 10.1167/IOVS.12-10476
F. Brignole-Baudouin, J.M. Warnet, D. Barritault, C. Baudouin, RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies. Journal Francais D Ophtalmologie. ,vol. 36, pp. 740- 747 ,(2013) , 10.1016/J.JFO.2013.01.012
Lee R. Katzman, Bennie H. Jeng, Management strategies for persistent epithelial defects of the cornea. Saudi Journal of Ophthalmology. ,vol. 28, pp. 168- 172 ,(2014) , 10.1016/J.SJOPT.2014.06.011
Keith Moore, Zachary J Bryant, Gautam Ghatnekar, Udai P Singh, Robert G Gourdie, Jay D Potts, None, A Synthetic Connexin 43 Mimetic Peptide Augments Corneal Wound Healing Experimental Eye Research. ,vol. 115, pp. 178- 188 ,(2013) , 10.1016/J.EXER.2013.07.001
I. De Monchy, A. Labbé, N. Pogorzalek, G. Gendron, M. M’Garrech, G. Kaswin, M. Labetoulle, Utilisation d’un agent biodégradable de la régénération tissulaire (RGTA) dans le traitement d’un ulcère trophique résistant d’origine zostérienne : à propos d’un cas Journal Francais D Ophtalmologie. ,vol. 35, pp. 1- 7 ,(2012) , 10.1016/J.JFO.2011.09.002
Ioannis Aslanides, Vasileios Selimis, Nikolaos Bessis, Panagiotis Georgoudis, A pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA). Clinical Ophthalmology. ,vol. 9, pp. 685- 690 ,(2015) , 10.2147/OPTH.S81061
C. Khammari Chebbi, K. Kichenin, N. Amar, H. Nourry, J.M. Warnet, D. Barritault, C. Baudouin, Étude pilote d’un nouvel agent de thérapie matricielle (RGTA OTR4120 ® ) dans les ulcères de cornée et les dystrophies cornéennes rebelles Journal Francais D Ophtalmologie. ,vol. 31, pp. 465- 471 ,(2008) , 10.1016/S0181-5512(08)72462-8